These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25267597)

  • 1. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
    Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
    Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
    Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
    Imai H; Komine K; Takahashi S; Saijo K; Okada Y; Kobayashi A; Okita A; Chikamatsu S; Kasahara Y; Takahashi M; Oishi T; Shirota H; Takahashi M; Shimodaira H; Ishioka C
    Chemotherapy; 2016; 61(5):262-8. PubMed ID: 27043795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.
    Yamamoto S; Kawakami H; Kii T; Hara H; Kawabata R; Kawada J; Takeno A; Matsuyama J; Ueda S; Okita Y; Endo S; Kimura Y; Yanagihara K; Okuno T; Kurokawa Y; Shimokawa T; Satoh T
    Eur J Cancer; 2021 Sep; 154():307-315. PubMed ID: 34311300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
    Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
    Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
    Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
    Muro K; Hamaguchi T; Ohtsu A; Boku N; Chin K; Hyodo I; Fujita H; Takiyama W; Ohtsu T
    Ann Oncol; 2004 Jun; 15(6):955-9. PubMed ID: 15151954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
    Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
    Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
    Abraham P; Gricar J; Zhang Y; Shankaran V
    Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
    Urakami S; Yoshino T; Kikuno N; Imai S; Honda S; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
    Urology; 2005 Mar; 65(3):543-8. PubMed ID: 15780373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
    Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
    Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
    Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
    Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
    Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
    Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
    Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
    BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.